1. ACTIV trials: cross-trial lessons learned for master protocol implementation
- Author
-
Maryam Keshtkar-Jahromi, Stacey J. Adam, Indira Brar, Lucy K. Chung, Judith S. Currier, Eric S. Daar, Victoria J. Davey, Eileen T. Denning, Annetine C. Gelijns, Elizabeth S. Higgs, Prasanna Jagannathan, Arzhang Cyrus Javan, Tomas O. Jensen, Nikolaus Jilg, Ioannis Kalomenidis, Peter Kim, Seema U. Nayak, Matthew Newell, Babafemi O. Taiwo, Tammy Yokum, and Yvette Delph
- Subjects
Accelerating COVID-19 Treatment Interventions and Vaccines ,COVID-19 ,clinical trial implementation ,master protocol ,preparedness ,trial platform ,Medicine - Abstract
The United States Government (USG) public-private partnership “Accelerating COVID-19 Treatment Interventions and Vaccines” (ACTIV) was launched to identify safe, effective therapeutics to treat patients with Coronavirus Disease 2019 (COVID-19) and prevent hospitalization, progression of disease, and death. Eleven original master protocols were developed by ACTIV, and thirty-seven therapeutic agents entered evaluation for treatment benefit. Challenges encountered during trial implementation led to innovations enabling initiation and enrollment of over 26,000 participants in the trials. While only two ACTIV trials continue to enroll, the recommendations here reflect information from all the trials as of May 2023. We review clinical trial implementation challenges and corresponding lessons learned to inform future therapeutic clinical trials implemented in response to a public health emergency and the conduct of complex clinical trials during “peacetime,” as well.
- Published
- 2024
- Full Text
- View/download PDF